



Contents lists available at ScienceDirect

Journal of Autoimmunity

journal homepage: [www.elsevier.com/locate/jautimm](http://www.elsevier.com/locate/jautimm)

## Cells with Treg-specific *FOXP3* demethylation but low CD25 are prevalent in autoimmunity

Ricardo C. Ferreira <sup>a, b</sup>, Henry Z. Simons <sup>b</sup>, Whitney S. Thompson <sup>b</sup>, Daniel B. Rainbow <sup>a, b</sup>, Xin Yang <sup>b</sup>, Antony J. Cutler <sup>a, b</sup>, Joao Oliveira <sup>b</sup>, Xaquín Castro Dopico <sup>b</sup>, Deborah J. Smyth <sup>b</sup>, Natalia Savinykh <sup>b</sup>, Meghavi Mashar <sup>b</sup>, Tim J. Vyse <sup>c</sup>, David B. Dunger <sup>d</sup>, Helen Baxendale <sup>e</sup>, Anita Chandra <sup>e</sup>, Chris Wallace <sup>b</sup>, John A. Todd <sup>a, b</sup>, Linda S. Wicker <sup>a, b, \*\*</sup>, Marcin L. Pekalski <sup>a, b, \*</sup>

<sup>a</sup> JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

<sup>b</sup> JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust/MRC Building, Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Research Campus, Cambridge, UK

<sup>c</sup> Department of Medical and Molecular Genetics, King's College Hospital, London, UK

<sup>d</sup> Department of Paediatrics, School of Clinical Medicine, University of Cambridge, Cambridge, UK

<sup>e</sup> Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK

### ARTICLE INFO

#### Article history:

Received 16 May 2017

Received in revised form

6 July 2017

Accepted 13 July 2017

Available online xxx

#### Keywords:

Regulatory T cells (Tregs)

Autoimmunity

*FOXP3*

Treg-specific demethylated region (TSDR)

CD25

### ABSTRACT

Identification of alterations in the cellular composition of the human immune system is key to understanding the autoimmune process. Recently, a subset of *FOXP3*<sup>+</sup> cells with low CD25 expression was found to be increased in peripheral blood from systemic lupus erythematosus (SLE) patients, although its functional significance remains controversial. Here we find in comparisons with healthy donors that the frequency of *FOXP3*<sup>+</sup> cells within CD127<sup>low</sup>CD25<sup>low</sup> CD4<sup>+</sup> T cells (here defined as CD25<sup>low</sup>*FOXP3*<sup>+</sup> T cells) is increased in patients affected by autoimmune disease of varying severity, from combined immunodeficiency with active autoimmunity, SLE to type 1 diabetes. We show that CD25<sup>low</sup>*FOXP3*<sup>+</sup> T cells share phenotypic features resembling conventional CD127<sup>low</sup>CD25<sup>high</sup>*FOXP3*<sup>+</sup> Tregs, including demethylation of the Treg-specific epigenetic control region in *FOXP3*, HELIOS expression, and lack of IL-2 production. As compared to conventional Tregs, more CD25<sup>low</sup>*FOXP3*<sup>+</sup>HELIOS<sup>+</sup> T cells are in cell cycle (33.0% vs 20.7% Ki-67<sup>+</sup>;  $P = 1.3 \times 10^{-9}$ ) and express the late-stage inhibitory receptor PD-1 (67.2% vs 35.5%;  $P = 4.0 \times 10^{-18}$ ), while having reduced expression of the early-stage inhibitory receptor CTLA-4, as well as other Treg markers, such as *FOXP3* and CD15s. The number of CD25<sup>low</sup>*FOXP3*<sup>+</sup> T cells is correlated ( $P = 3.1 \times 10^{-7}$ ) with the proportion of CD25<sup>high</sup>*FOXP3*<sup>+</sup> T cells in cell cycle (Ki-67<sup>+</sup>). These findings suggest that CD25<sup>low</sup>*FOXP3*<sup>+</sup> T cells represent a subset of Tregs that are derived from CD25<sup>high</sup>*FOXP3*<sup>+</sup> T cells, and are a peripheral marker of recent Treg expansion in response to an autoimmune reaction in tissues.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

### 1. Introduction

*FOXP3*<sup>+</sup> regulatory T cells (Tregs) are produced in the thymus as

a specific T cell lineage following high affinity TCR engagement that results in the demethylation of the Treg-specific demethylated region (TSDR) in *FOXP3* and stable *FOXP3* expression [1]. Following emigration from the thymus and activation, naïve Tregs proliferate and differentiate into memory Tregs that are actively recruited to peripheral compartments to suppress immune responses against self-antigen and maintain tissue integrity [2]. It is becoming increasingly apparent that there is considerable heterogeneity in memory Treg subsets in humans [3,4]. One major challenge for studying human Tregs is that in general peripheral blood cells from

\* Corresponding author. Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

\*\* Corresponding author. Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

E-mail addresses: [linda.wicker@well.ox.ac.uk](mailto:linda.wicker@well.ox.ac.uk) (L.S. Wicker), [marcin.pekalski@well.ox.ac.uk](mailto:marcin.pekalski@well.ox.ac.uk) (M.L. Pekalski).

<http://dx.doi.org/10.1016/j.jaut.2017.07.009>

0896-8411/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

patients are more readily available, rather than the effector T cells and Tregs present in the inflamed tissue and associated lymph nodes. A better understanding of the composition of the Treg compartment in peripheral blood is therefore needed to investigate the potential contribution to disease made by Tregs and to identify cellular alterations of the peripheral compartment associated with the onset of pathogenic autoimmune destruction of the targeted tissue.

Recently, a subset of FOXP3<sup>+</sup> CD4<sup>+</sup> T cells with low expression of CD25 was reported to be increased in peripheral blood of autoimmune systemic lupus erythematosus (SLE) patients [5–9], a finding that was later expanded to the peripheral blood of multiple sclerosis [10] and rheumatoid arthritis [11] patients. The frequency of this cell subset has been demonstrated to be associated with increased SLE disease activity in one study [7] but not in another [5]. Nevertheless, in this second study the frequency of CD25<sup>low</sup> FOXP3<sup>+</sup> T cells was correlated with dsDNA antibodies levels [5,7] suggesting that these cells may be directly pathogenic or biomarkers of autoimmunity in these patients. However, their origin and function in SLE patients and healthy individuals remain ambiguous [12,13]. In the present study, we characterise these CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> CD4<sup>+</sup> T cells (henceforth designated as CD25<sup>low</sup>FOXP3<sup>+</sup> cells), and demonstrate that they share phenotypic features with Tregs, including demethylation of the FOXP3 TSDR and constitutive expression of the transcription factor HELIOS in a majority of the cells, and an inability to produce IL-2 compared to FOXP3<sup>+</sup> Tregs. However, compared to conventional CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs, CD25<sup>low</sup>FOXP3<sup>+</sup> cells showed increased expression of activation and proliferation markers such as PD-1 and Ki-67, and reduced expression of Treg-associated molecules, including FOXP3 and CTLA-4. We suggest that these cells represent the last stage of the natural life-cycle of TSDR-demethylated Tregs *in vivo* and that chronic stimulation in the form of active autoimmunity increases their prevalence.

## 2. Methods

### 2.1. Subjects

Study participants included 34 SLE patients recruited from Guy's and St Thomas' NHS Foundation Trust. All patients satisfied ACR SLE classification criteria and were allocated a disease activity using SLEDAI-2K at the time of sampling. SLE patients were recruited from a clinic in which the severity of disease was such that none of the patients were on high dose oral corticosteroids (>15 mg/day) or B-cell depleting therapy. SLE patients were compared to a cohort of 24 age- and sex-matched healthy donors from the Cambridge BioResource (CBR). A second cohort of 112 healthy donors from the CBR was used for the analysis of Ki-67 expression within the assessed T cell subsets.

Combined immunodeficiency patients (CID; N = 7) were recruited from Cambridge University Hospitals and Papworth Hospital NHS Foundation Trusts, and compared to six age- and sex-matched healthy donors from the CBR. Patients were selected on the presentation of immune infiltration in the lungs and active autoimmunity in the absence of a known genetic cause, although the clinical symptoms were consistent with those associated with recently characterised *CTLA4* germline mutations [14]. All CID patients were treated with immunoglobulin replacement therapy and prophylactic antibiotics.

Adult long-standing T1D patients (N = 15) and healthy controls (HC; N = 15) were recruited from the CBR. Newly diagnosed T1D patients (ND; N = 49) and unaffected siblings of other T1D probands (N = 40) were collected from the JDRF Diabetes–Genes, Autoimmunity and Prevention (D-GAP) study (<http://paediatrics.medschl.cam.ac.uk/research/clinical-trials/>).

ND patients were characterised as having been diagnosed with T1D less than two years prior to their blood donation (with one exception of 42 months). Unaffected siblings were islet autoantibody-negative (IAA, IA2, GAD and ZnT8), and were not related to any T1D patient included in this study. All donors were of white ethnicity and all healthy controls and unaffected siblings were individuals without autoimmune disease (self-reported). Baseline characteristics for all participating subjects are summarised in Table 1.

### 2.2. Ethics

All samples and information were collected with written and signed informed consent. The D-GAP study was approved by the Royal Free Hospital & Medical School research ethics committee; REC (08/H0720/25). Adult long-standing T1D patients and healthy volunteers were enrolled in the CBR. The study was approved by the local Peterborough and Fenland research ethics committee (05/Q0106/20). Informed consent was obtained from CID patients, parents, or both (R&D Ref: P01685, REC Ref: 12/WA/0148) and from SLE patients (REC Ref: 07/H0718/49). The study conformed to the Declaration of Helsinki and all local ethical requirements.

### 2.3. PBMC sample preparation

PBMCs were isolated by Ficoll gradient centrifugation and cryopreserved in 10% heat-inactivated human AB serum, as described previously [15]. T1D patients and healthy controls were recruited contemporaneously and samples were processed and stored by the same investigators to prevent spurious findings caused by differential sample preparation.

Cryopreserved PBMCs (10 × 10<sup>6</sup> per donor) were thawed at 37 °C and resuspended in X-VIVO (Lonza) + 1% heat-inactivated, filtered human AB serum (Sigma). Cell viability following resuscitation was assessed in a subset of 40 donors using the Fixable Viability Dye eFluor 780 (eBioscience) and was found to be consistently very high (95.6%; min = 86.8%, max = 98.2%) for all samples analysed in this study.

**Table 1**

Baseline characteristics of study participants included in the association analyses.

Cohort	N	Age (years)		Male N (%)
		Median	Range	
SLE	34	36	20–72	2 (5.9%)
Healthy controls (CBR) - cohort 1	24	42	22–62	1 (4.2%)
Healthy controls (CBR) - cohort 2	112	49	26–78	30 (26.8%)
CID	7	23	13–45	5 (71.4%)
Healthy controls (CBR)	6	34	17–47	4 (66.7%)
<b>T1D discovery cohort</b>				
T1D (D-GAP) <sup>a</sup>	49	13	6–34	32 (65.3%)
T1D (CBR) <sup>b</sup>	15	32	22–32	5 (33.3%)
T1D (combined)	64	14	6–42	37 (58.0%)
Unaffected Siblings (D-GAP) <sup>c</sup>	40	13	6–31	21 (52.5%)
Healthy Controls (CBR)	15	27	18–37	4 (26.7%)
Healthy controls (combined)	55	15	6–37	28 (45.9%)
<b>T1D replication cohort</b>				
T1D (CBR)	15	37	17–52	5 (33.3%)
Healthy Controls (CBR)	15	37	22–47	4 (26.7%)

Baseline characteristics for the study participants stratified by the study cohorts.

<sup>a</sup> Newly diagnosed T1D patients (duration of disease ≤ 3 years) enrolled in the Diabetes - Genes, Autoimmunity and Prevention (D-GAP) study.

<sup>b</sup> Long-standing adult T1D patients enrolled from the Cambridge BioResource (CBR).

<sup>c</sup> First-degree sibling of a T1D patient, reporting no autoimmune disease and determined to be negative for the following T1D-associated autoantibodies: IAA, IA2, GAD and ZnT8. CID, Combined immunodeficiency; T1D, type 1 diabetes; SLE; systemic lupus erythematosus.

#### 2.4. Cell culture and in vitro stimulation

To reduce the effects of experimental variation and other potential covariates, PBMC samples were processed in batches of a minimum of ten samples per day. T1D patients and healthy controls were matched as closely as possible for age (within 5 year age-bands), sex and time of sample preparation.

After thawing, PBMCs were resuspended in RPMI medium (Gibco) supplemented with 10% FBS, 2 mM L-Glutamine and 100 µg/mL Pen-Strep and cultured ( $10^6$  PBMCs/well) in 24-well flat-bottom cell culture plate (BD). For cytokine production assays, cells were initially rested for 30 min at 37 °C and then cultured in the presence or absence of 5 ng/mL PMA, 100 ng/mL ionomycin and 0.67 µl/mL Monensin GolgiStop (BD Biosciences) for 4 h at 37 °C. For a subset of 66 donors,  $10^6$  cells were cultured with medium alone and 0.67 µl/mL Monensin to determine background levels of cytokine production in unstimulated cells.

#### 2.5. Intracellular immunostainings

After activation, PBMCs were harvested, and stained with Fixable Viability Dye eFluor 780 for 20 min at 4 °C. Cells were then stained with fluorochrome-conjugated antibodies against surface receptors (see [Supplementary Table 1](#)) for 1 h at 4 °C. Fixation and permeabilisation was performed using FOXP3 Fix/Perm Buffer Set (BioLegend) and cells were then stained with intracellular antibodies for 1 h at 4 °C (see [Supplementary Table 1](#)). All experiments were performed in an anonymised, blinded manner without prior knowledge of disease state.

#### 2.6. Flow cytometry

Immunostained samples were acquired using a BD Fortessa (BD Biosciences) flow cytometer with FACSDiva software (BD Biosciences) and analysed using FlowJo (Tree Star, Inc.). Dead-cell exclusion based on the Fixable Viability Dye was performed for the intracellular immunostainings.

#### 2.7. Analysis of the epigenetic demethylation profile by next-generation sequencing

Total PBMCs from seven healthy CBR donors (three males and four females) were stained with fluorophore-conjugated antibodies (see [Supplementary Table 1](#)) and sorted using a BD Aria Fusion flow cytometer (BD Biosciences). Methylation of the FOXP3 TSDR was performed using a next-generation sequencing method, as described previously [16].

#### 2.8. Statistical analyses

Statistical analyses were performed using Prism software (GraphPad) and Stata ([www.stata.com](http://www.stata.com)). Association of the frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> T cells with T1D, SLE and CID was calculated using two-tailed unpaired student's t-tests. The effects of age, sex and time of collection were controlled by the experimental design used in this study and, therefore, not included as additional covariates. Given that most immune phenotypes showed moderate to strong right skew that violated the assumption of normality, the phenotypes were log-transformed before statistical testing.

Comparison of the expression of the interrogated immune markers between CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> CD4<sup>+</sup> T cells and: (i) CD25<sup>high</sup>FOXP3<sup>+</sup>, (ii) CD25<sup>high</sup>FOXP3<sup>-</sup> and (iii) CD25<sup>low</sup>FOXP3<sup>-</sup> CD4<sup>+</sup> T cells was performed within individuals using two-tailed paired student's t-tests. The correlations between immune subsets were calculated using linear regression analysis.

To account for the issue of multiple testing we applied a conservative Bonferroni correction to determine the thresholds for significant results: (i) for the comparison of the frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> T cells between healthy donors and patients from three different autoimmune diseases, we considered *P* values < 0.0167 significant (Bonferroni correction for three independent tests); (ii) for the comparison of the ten assessed immune markers between the CD25<sup>low</sup> and CD25<sup>high</sup> Treg subsets, we considered *P* values < 0.005 significant (Bonferroni correction for ten independent tests).

### 3. Results

#### 3.1. Frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> T cells is increased in blood from patients with active autoimmunity


To investigate the peripheral alterations in FOXP3<sup>+</sup> T cell subsets, we performed a detailed immunophenotyping characterisation of cryopreserved peripheral blood mononuclear cells (PBMCs) of different cohorts of patients with autoimmune disease (summarised in [Table 1](#)). Analysis of the flow cytometry profile of patients with systemic autoimmunity as compared to healthy donors revealed that the frequency of FOXP3<sup>+</sup> CD4<sup>+</sup> T cells is highly increased in CD127<sup>low</sup> cells of some patients. We found that among SLE and CID patients with increased CD127<sup>low</sup> FOXP3-expressing cells there is a notable loss of CD25 expression, which results in an extremely high frequency of CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> cells ([Fig. 1A](#)). These findings suggest that the frequency of FOXP3<sup>+</sup> cells in the CD127<sup>low</sup>CD25<sup>low</sup> T cell subset (CD25<sup>low</sup>FOXP3<sup>+</sup> cells; depicted in red in [Fig. 1B](#)) is increased as a result of an active autoimmune response and could be a specific marker of Treg activation. Given the lack of peripheral markers that reflect chronic immune activation, we therefore decided to focus our analysis on this population of CD25<sup>low</sup>FOXP3<sup>+</sup> cells, and investigate their frequency in the peripheral blood of autoimmune patients.

Consistent with previous findings [7,8], we confirmed that the frequency of FOXP3<sup>+</sup> cells among CD127<sup>low</sup>CD25<sup>low</sup> T cells (gating strategy [Fig. 1B](#)) was markedly increased in SLE patients (geometric mean (GeoM) = 13.5%) compared to age- and sex-matched healthy controls (5.5%, *P* =  $2.1 \times 10^{-5}$ , *N* = 24, [Fig. 1C](#)), which likely reflects the systemic immune activation in SLE patients. In support of this hypothesis, we also detected a high frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells in a small cohort of seven CID patients, characterised by severe active autoimmunity compared to age- and sex-matched healthy controls (12.1% and 4.0%, respectively, *P* =  $6.5 \times 10^{-3}$ ; [Fig. 1C](#)).

We also found that the frequency of FOXP3<sup>+</sup> cells among CD127<sup>low</sup>CD25<sup>low</sup> T cells was significantly increased in T1D patients (6.8%) compared to age- and sex-matched healthy controls (4.6%; *P* =  $2.7 \times 10^{-6}$ ; [Fig. 1D](#)). This association was also observed when comparing the frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells within total CD4<sup>+</sup> T cells (0.32% vs 0.23% in T1D patients and controls, respectively; *P* =  $1.1 \times 10^{-3}$ ; [Supplementary Fig. 1A](#)). We replicated the finding of increased FOXP3<sup>+</sup> cells among CD127<sup>low</sup>CD25<sup>low</sup> T cells in an independent cohort of 15 long-standing T1D patients (10.39%) and 15 age- and sex-matched healthy controls (6.3%; *P* =  $7.7 \times 10^{-3}$ ; [Supplementary Fig. 1B](#)). Furthermore, we noted that the increased frequency of FOXP3<sup>+</sup> cells was mainly restricted to the CD127<sup>low</sup>CD25<sup>low</sup> T cell subset, as we observed only a small increased frequency of conventional CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs in T1D patients (5.6%) compared to healthy donors (4.8%; *P* =  $8.0 \times 10^{-3}$ ; [Supplementary Fig. 2](#)).

SLE disease activity index (SLEDAI) scores were available from 33 SLE patients evaluated for the frequency of CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> Tregs. We noted that there was a trend towards increased frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells with






**Fig. 1. Frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells is increased in patients with autoimmune disease.** (A) Patterns of CD25 and FOXP3 expression among CD127<sup>low</sup> CD4<sup>+</sup> T cells from healthy donors and patients with autoimmune manifestations. (B) Gating strategy for the delineation of the T-cell subsets characterised in this study. Distribution of FOXP3<sup>+</sup> cells among: (i) CD127<sup>low</sup>CD25<sup>high</sup> conventional Tregs (depicted in blue); and (ii) CD127<sup>low</sup>CD25<sup>low</sup> T cells (depicted in red). The vertical dotted line represents the threshold for the gating of FOXP3<sup>+</sup> cells (histograms). (C, D) Scatter plots depict the frequency (geometric mean  $\pm$  95% CI) of FOXP3<sup>+</sup> cells among CD127<sup>low</sup>CD25<sup>low</sup> T cells in SLE patients (N = 34 patients vs 24 healthy donors) and combined immunodeficiency patients with active autoimmunity (N = 7 patients vs 6 healthy donors) (C); or in a cohort of T1D patients (N = 62; depicted by red circles) and healthy donors (N = 54; depicted by black squares) (D). P values were calculated using two-tailed unpaired t-tests. P values < 0.0167 were considered significant (Bonferroni correction for the comparison in three different diseases). The initial CD4<sup>+</sup> T cell gate (CD4 versus dead cell exclusion dye) was derived from a lymphocyte gate (defined on forward and side scatter) followed by single-cell discrimination. HC, healthy controls; T1D, type 1 diabetes patients; SLE, systemic lupus erythematosus patients; CID, combined immunodeficiency patients. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

increased SLEDAI at the time of sampling, although it did not reach statistical significance (Supplementary Fig. 3A). Previously a correlation between disease activity and frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells was reported [7], whereas another study did not [5]. These apparently conflicting results could be due to disease heterogeneity and relatively small sample sizes. Future longitudinal studies assessing the frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells in SLE and other autoimmune patients with high levels of this Treg subset before and following drug treatments will aid in resolving this uncertainty. In the T1D patients, the frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells was not associated with duration of disease indicating that the increased level of CD25<sup>low</sup> Tregs in T1D is not restricted to the time of disease diagnosis (Supplementary Fig. 3B). The analysis was restricted to the 49 recently diagnosed T1D patients (median 11 months, range 2–42 months) from the D-GAP cohort, which was a much larger cohort and displayed a more homogeneous distribution of time since diagnosis compared to the cohort of long-standing diabetics.

### 3.2. CD25<sup>low</sup>FOXP3<sup>+</sup> cells are demethylated at the FOXP3 TSDR

In humans FOXP3 is not exclusively expressed in Tregs, but can also be transiently up-regulated in activated Teffs. However, in thymically-derived Tregs constitutive expression of FOXP3 is known to require a demethylated TSDR [2]. To assess the TSDR methylation profile of CD25<sup>low</sup>FOXP3<sup>+</sup> cells we sorted these cells from four healthy donors, and compared the methylation of the TSDR in CD25<sup>low</sup>FOXP3<sup>+</sup> cells, conventional CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs and the respective FOXP3<sup>-</sup> subsets (Fig. 2A). We found that the majority of CD25<sup>low</sup>FOXP3<sup>+</sup> cells were demethylated at the TSDR (Fig. 2B and C). The epigenetic demethylation pattern in CD25<sup>low</sup>FOXP3<sup>+</sup> cells was similar to CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs at all nine interrogated CpG sites in the FOXP3 TSDR (mean = 57.1% and 80.5% demethylation, respectively; Fig. 2B); in contrast, <7% of CD25<sup>low</sup>FOXP3<sup>-</sup> and CD25<sup>high</sup>FOXP3<sup>-</sup> cells had demethylated TSDRs. These findings indicate that the majority of CD25<sup>low</sup>FOXP3<sup>+</sup> cells are *bona fide* Tregs, and are not Teffs transiently upregulating FOXP3 expression as a result of immune activation.



**Fig. 2.** CD25<sup>low</sup>FOXP3<sup>+</sup> cells are demethylated at the FOXP3 Treg-specific demethylated region (TSDR). (A) Gating strategy for FACS sorting of four CD4<sup>+</sup> T-cell subsets: (i) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>-</sup> (depicted in green), (ii) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> (depicted in red), (iii) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>-</sup> (depicted in grey), and (iv) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (depicted in blue). (B) Frequency (mean ± SEM) of reads demethylated at eight or nine of the nine interrogated CpG sites in the FOXP3 TSDR. The data were obtained from sorted cells from four independent healthy donors. (C) Graphic depicts the proportion of demethylated reads at the nine interrogated CpG sites from the FOXP3 TSDR in one illustrative donor. Each horizontal line represents one sequencing read, with light green representing a methylated read (C) and dark green representing a demethylated read (T). Note that the plot is representative of a male donor. For female donors, X-chromosome inactivation causes half of the reads to be methylated and a correction factor of two was applied to obtain the frequency of demethylated reads. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)


### 3.3. CD25<sup>low</sup>FOXP3<sup>+</sup> cells express the Treg-specific HELIOS transcription factor and exhibit features of an activated phenotype

Having established that a majority of CD25<sup>low</sup>FOXP3<sup>+</sup> cells are stably demethylated at the FOXP3 TSDR, we next performed a detailed phenotypic characterisation of this subset by flow cytometry in 24 healthy adult donors to investigate phenotypic similarities and differences between CD25<sup>low</sup>FOXP3<sup>+</sup> and classical Tregs (CD25<sup>high</sup>FOXP3<sup>+</sup>). One distinguishing feature of these cells was the higher frequency of memory phenotype (CD45RA<sup>-</sup>) cells compared to their CD25<sup>high</sup>FOXP3<sup>+</sup> counterparts (83.8% and 64.7% CD45RA<sup>-</sup> cells, respectively;  $P = 2.0 \times 10^{-11}$ ; Fig. 3A). This difference was particularly noticeable among the younger cohort (median age = 14 years) of 116 T1D patients and unaffected siblings (76.9% and 43.4%, respectively;  $P = 1.2 \times 10^{-58}$ ; Fig. 3B), which have a higher proportion of CD45RA<sup>+</sup> naive cells amongst their

CD25<sup>high</sup>FOXP3<sup>+</sup> conventional Tregs compared to adult donors, suggesting that the majority of CD25<sup>low</sup>FOXP3<sup>+</sup> cells have responded previously to antigen, or have expanded in an antigen-independent manner, following their emigration from the thymus. Since the majority of CD25<sup>low</sup>FOXP3<sup>+</sup> cells are CD45RA<sup>-</sup>, we focused further analyses on memory FOXP3<sup>+</sup> cells.

We found that an increased frequency of CD45RA<sup>-</sup> CD25<sup>low</sup>FOXP3<sup>+</sup> cells express the proliferation marker Ki-67 compared to their CD25<sup>high</sup>FOXP3<sup>+</sup> counterparts (29.9% and 22.0%, respectively;  $P = 2.7 \times 10^{-7}$ ; Fig. 3C). In addition to Ki-67, CD45RA<sup>-</sup> CD25<sup>low</sup>FOXP3<sup>+</sup> cells were also characterised by a marked increased frequency of PD-1<sup>+</sup> cells compared to CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs (65.1% and 38.3%, respectively;  $P = 1.7 \times 10^{-17}$ ; Fig. 3D), and had a frequency of PD-1<sup>+</sup> cells more similar to their CD25<sup>low</sup>FOXP3<sup>-</sup> counterparts (67.2%; Fig. 3D).


Furthermore, we demonstrated that, similarly to



**Fig. 3. CD25<sup>low</sup>FOXP3<sup>+</sup> T cells display a memory phenotype.** (A, B) Representative histograms and summary scatter plots depict the frequency (geometric mean  $\pm$  95% CI) of CD45RA<sup>-</sup> memory T cells amongst the CD25<sup>low</sup>FOXP3<sup>-</sup> and CD25<sup>low</sup>FOXP3<sup>+</sup> subsets in a population of 24 adult (median age = 42 years) healthy donors (A) or in a population of 116 younger (median age = 14 years) T1D patients (N = 62) and healthy donors (N = 54) (B). (C, D) Representative histograms and the frequency distribution (geometric mean  $\pm$  95% CI) of Ki-67<sup>+</sup> (C) and PD-1<sup>+</sup> (D) cells in the CD45RA<sup>-</sup> compartment of the four assessed immune subsets. P values < 0.005 were considered significant (Bonferroni correction for the comparison of ten independent immune markers between CD25<sup>low</sup>FOXP3<sup>+</sup> and CD25<sup>high</sup>FOXP3<sup>+</sup> T cells). Gating strategy to delineate: (i) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>-</sup> (highlighted in green), (ii) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> (highlighted in red), (iii) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>-</sup> (highlighted in grey), and (iv) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (highlighted in blue) CD4<sup>+</sup> T cells is depicted in Fig. 2A. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

CD25<sup>high</sup>FOXP3<sup>+</sup> CD45RA<sup>-</sup> memory Tregs, the majority of CD25<sup>low</sup>FOXP3<sup>+</sup> CD45RA<sup>-</sup> memory cells also express the transcription factor HELIOS, although the proportion of HELIOS<sup>+</sup> cells was significantly lower (51.1%) compared to CD25<sup>high</sup>FOXP3<sup>+</sup> CD45RA<sup>-</sup> memory Tregs (77.8%;  $P = 3.0 \times 10^{-12}$ ; Fig. 4A and B). Consistent with the reduction in CD25 and HELIOS, CD25<sup>low</sup>FOXP3<sup>+</sup>

cells also showed a significantly lower expression of other classical Treg markers compared to CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs, such as TIGIT (65.1% vs 78.0%;  $P = 3.7 \times 10^{-8}$ ), CD15s (20.7% vs 33.5%;  $P = 5.8 \times 10^{-12}$ ) and most notably, CTLA-4 (60.0% vs 84.7%;  $P = 9.4 \times 10^{-11}$ ; Fig. 4A and B). Furthermore, we found that the expression of FOXP3 was markedly lower in CD25<sup>low</sup>FOXP3<sup>+</sup> cells



**Fig. 4.** CD25<sup>low</sup>FOXP3<sup>+</sup> cells show reduced expression of several conventional Treg markers. (A) Representative histograms depict the distribution of the expression of the conventional Treg markers HELIOS, TIGIT, CD15s and CTLA-4 amongst: (i) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>-</sup> (highlighted in green), (ii) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> (highlighted in red), (iii) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>-</sup> (highlighted in grey), and (iv) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (highlighted in blue) memory CD4<sup>+</sup> T cells. (B) Scatter plots depict the distribution (geometric mean  $\pm$  95% CI) of HELIOS (n = 24), TIGIT (n = 24), CD15s (n = 24) and CTLA-4 (n = 13) in the CD45RA<sup>-</sup> compartment of the four assessed immune subsets. (C) Expression of FOXP3 (geometric mean  $\pm$  95% CI) was measured in the CD25<sup>low</sup>FOXP3<sup>+</sup> (depicted by red squares) and CD25<sup>high</sup>FOXP3<sup>+</sup> (depicted by blue circles) subsets from 24 healthy donors. *P* values were calculated using two-tailed paired t-tests comparing the assessed immunophenotypes between CD25<sup>low</sup>FOXP3<sup>+</sup> and the other three delineated subsets from the same individual. *P* values < 0.005 were considered significant (Bonferroni correction for the comparison of ten independent immune markers between CD25<sup>low</sup>FOXP3<sup>+</sup> and CD25<sup>high</sup>FOXP3<sup>+</sup> T cells). MFI, mean fluorescence intensity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

compared to CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs (MFI = 1171 and 2160 respectively,  $P = 3.6 \times 10^{-11}$ ; Fig. 4C), suggesting that CD25<sup>low</sup>FOXP3<sup>+</sup> cells show a decreased expression of classical Treg-associated molecules.


#### 3.4. HELIOS<sup>+</sup>CD45RA<sup>-</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> cells are demethylated at the FOXP3 TSDR to the same degree as conventional HELIOS<sup>+</sup>CD45RA<sup>-</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs

To further investigate the methylation profile of FOXP3<sup>+</sup> cells, we next assessed the TSDR methylation in the HELIOS<sup>+</sup> and HELIOS<sup>-</sup> subsets in three additional healthy donors. In agreement with their putative Treg lineage, we confirmed that the HELIOS<sup>+</sup> subsets of both CD25<sup>low</sup>FOXP3<sup>+</sup> cells and conventional CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs are virtually completely demethylated at the FOXP3 TSDR (>95%; Fig. 5A). In contrast, the HELIOS<sup>-</sup> subsets of CD25<sup>low</sup>FOXP3<sup>+</sup> cells and conventional CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs contained a much lower proportion of cells demethylated at the TSDR (21% and 64%, respectively), to investigate if the FOXP3 methylation status of CD25<sup>low</sup>FOXP3<sup>+</sup> cells was maintained in autoimmune patients, we also assessed the TSDR methylation in three SLE patients recalled based on an increased frequency of CD25<sup>low</sup>FOXP3<sup>+</sup> cells. Consistent with the results obtained from healthy donors, we

found that HELIOS<sup>+</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> cells were fully demethylated at the FOXP3 TSDR (>95%; Supplementary Fig. 4).

Since HELIOS expression is highly enriched in FOXP3<sup>+</sup> cells demethylated at the TSDR, we examined other phenotypes within the FOXP3<sup>+</sup> cells stratified by HELIOS expression. CD25<sup>low</sup>FOXP3<sup>+</sup> cells demethylated at the TSDR as defined by HELIOS expression had a higher proportion in cell cycle as compared to CD25<sup>high</sup>FOXP3<sup>+</sup> cells expressing HELIOS (33.0% and 20.7%, respectively; Fig. 5B and C). In addition, the proportion of cells expressing PD-1 and the per cell level of PD-1 were both increased on CD25<sup>low</sup>FOXP3<sup>+</sup> demethylated at the TSDR as compared to their CD25<sup>high</sup> counterparts (Fig. 5B and C). Expression of TIGIT, CTLA-4 and CD15s were also compared (Supplementary Figs. 5A–D) with HELIOS stratification revealing a high percentage (>89%) of TIGIT<sup>+</sup> cells in both populations of demethylated FOXP3<sup>+</sup> cells, but a reduced number expressing CD15s and CTLA-4 in the CD25<sup>low</sup>FOXP3<sup>+</sup> cells demethylated at the TSDR as compared to their CD25<sup>high</sup> counterparts. High expression of CTLA-4 was present on CD25<sup>high</sup>FOXP3<sup>+</sup>HELIOS<sup>-</sup> cells, a population with >50% of the cells having a demethylated TSDR (Fig. 5A). Expression of FOXP3 was found to be significantly higher within both conventional CD25<sup>high</sup> Tregs (MFI > 2100) compared to CD25<sup>low</sup>FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells (MFI = 1590), despite their demethylated TSDR. Notably, the





**Fig. 5.** HELIOS<sup>+</sup> CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells are demethylated at TSDR as much as conventional HELIOS<sup>+</sup> CD45RA<sup>-</sup> CD25<sup>high</sup> FOXP3<sup>+</sup> Tregs. Frequency (mean ± SEM) of reads demethylated at eight or nine of the nine interrogated CpG sites in the FOXP3 TSDR in CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells and CD45RA<sup>-</sup> CD25<sup>high</sup> FOXP3<sup>+</sup> Tregs stratified by the expression of HELIOS. The data were obtained from sorted cells from three independent healthy donors.

expression of FOXP3 was markedly lower in CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>-</sup> T cells (MFI = 952), which is consistent with their methylated TSDR (Supplementary Fig. 5E). Furthermore, analysis of CD45RA<sup>+</sup> expression revealed a significantly lower frequency of CD45RA<sup>+</sup> cells within total CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> cells (4.7%) compared to their CD25<sup>high</sup> counterparts (20.8%;  $P = 2.0 \times 10^{-12}$ ; Supplementary Fig. 5F). These data suggest that most of the CD45RA<sup>+</sup> cells observed within CD25<sup>low</sup> FOXP3<sup>+</sup> T cells are memory effector T cells that have re-expressed CD45RA on their surface and are characterised by being HELIOS<sup>-</sup> and expressing lower levels of FOXP3. Finally, since it was possible that the expansion of CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>-</sup> cells (most of which lack a demethylated TSDR and might be activated effector cells) could have been responsible for the increase of CD25<sup>low</sup> FOXP3<sup>+</sup> cells in autoimmune patients (Fig. 1B and C), we examined the distribution of HELIOS<sup>+</sup> and HELIOS<sup>-</sup> cells within the CD25<sup>low</sup> FOXP3<sup>+</sup> subset. We determined that HELIOS<sup>+</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells were increased in SLE, CID and T1D patients as compared to their healthy control cohorts (Supplementary Figs. 6A and B) similar to the findings with CD25<sup>low</sup> FOXP3<sup>+</sup> cells (Fig. 1C and D) and that HELIOS<sup>+</sup> cells contributed significantly to all cohorts examined (Supplementary Figs. 6C and D).


### 3.5. Low IL-2 production from HELIOS<sup>+</sup> CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells

To characterise the function of HELIOS<sup>+</sup> CD45RA<sup>-</sup>

CD25<sup>low</sup> FOXP3<sup>+</sup> cells, we assessed the production of two key cytokines, IL-2 and IFN- $\gamma$ , in ten donors (five T1D patients and five healthy controls) following *in vitro* stimulation (Fig. 6). Consistent with their Treg-like phenotype, we found that both the HELIOS<sup>+</sup> CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> and CD25<sup>high</sup> FOXP3<sup>+</sup> subsets, which are highly demethylated at the TSDR (Fig. 5A), showed a low frequency of IL-2<sup>+</sup> (2.0% and 1.0%, respectively) and IFN- $\gamma$ <sup>+</sup> cells (5.1% and 1.4%, respectively; Fig. 6B and C). This was in marked contrast with the HELIOS<sup>+</sup> CD25<sup>low</sup> FOXP3<sup>-</sup> subset, which was found to secrete significantly higher levels of both IL-2 (21.3%;  $P = 2.8 \times 10^{-5}$ ; Fig. 6B) and IFN- $\gamma$  (27.9%;  $P = 1.1 \times 10^{-3}$ ; Fig. 6C), compared their FOXP3<sup>+</sup> counterparts (2.0% and 5.1% for IL-2 and IFN- $\gamma$ , respectively). In agreement with their regulatory phenotype, we found a strong reduction of IL-2<sup>+</sup> and IFN- $\gamma$ <sup>+</sup> cells (2.0% and 5.1%, respectively) in HELIOS<sup>+</sup> CD45RA<sup>-</sup> CD127<sup>low</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells compared to conventional Tregs (59.8%,  $P = 5.3 \times 10^{-9}$  and 63.5%,  $P = 2.0 \times 10^{-7}$  for IL-2<sup>+</sup> and IFN- $\gamma$ <sup>+</sup> cells, respectively; Fig. 6B and C).

As compared to the HELIOS<sup>+</sup> fraction, we found that a higher portion of HELIOS<sup>-</sup> CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells produced IFN- $\gamma$  (Fig. 6A, Supplementary Fig. 7A). These findings are consistent with a previous study, showing that HELIOS<sup>-</sup> FOXP3<sup>+</sup> T cells produced IFN- $\gamma$ , and were increased among T1D patients [17]. Although we found no evidence for differential IFN- $\gamma$  production in T1D patients compared to healthy controls among HELIOS<sup>-</sup> CD45RA<sup>-</sup> CD127<sup>low</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> cells, on a per cell basis (Supplementary Fig. 7B), the higher frequency of the






**Fig. 6. HELIOS<sup>+</sup>CD45RA<sup>-</sup> CD25<sup>low</sup>FOXP3<sup>+</sup> cells show impaired production of IL-2 and IFN- $\gamma$ .** (A) Gating strategy to delineate the CD45RA<sup>-</sup>HELIOS<sup>+</sup> subset of: (i) CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> (highlighted in red), (ii) CD127<sup>low</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (highlighted in blue), and (iii) CD127<sup>+</sup>CD25<sup>low/+</sup>FOXP3<sup>-</sup> HELIOS<sup>-</sup> conventional (Conv) effector (highlighted in black) subsets of CD4<sup>+</sup> T cells. (B, C) Bar graphs depict the frequency (mean  $\pm$  95% CI) of IL-2<sup>+</sup> and IFN- $\gamma$ <sup>+</sup> cells in the CD45RA<sup>-</sup>HELIOS<sup>+</sup> compartment (or the CD45RA<sup>-</sup>HELIOS<sup>-</sup> compartment in the case of the conventional effector T cells) of the five assessed immune subsets depicted in panel A. Cytokine production was assessed in ten independent batches of ten donors. *P* values were calculated using two-tailed paired *t*-tests. *P* values < 0.005 were considered significant (Bonferroni correction for the comparison of ten independent immune markers between CD25<sup>low</sup>FOXP3<sup>+</sup> and CD25<sup>high</sup>FOXP3<sup>+</sup> T cells). FACS gating plots depict data from one illustrative donor. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

CD25<sup>low</sup>FOXP3<sup>+</sup> subset among patients resulted in a significant increase in the frequency of circulating FOXP3<sup>+</sup> cells with the capability to produce IFN- $\gamma$  following stimulation among total CD4<sup>+</sup> T cells ( $P = 2.5 \times 10^{-3}$ ; Supplementary Fig. 7C). These data suggest that HELIOS<sup>-</sup> CD45RA<sup>-</sup> CD127<sup>low</sup>CD25<sup>low</sup>FOXP3<sup>+</sup> cells contributed to the increased frequency of IFN- $\gamma$ <sup>+</sup> cells reported among FOXP3<sup>+</sup> cells from T1D patients [17].

### 3.6. CD25<sup>low</sup>FOXP3<sup>+</sup> T cells are highly correlated with proliferating CD25<sup>high</sup>FOXP3<sup>+</sup> Tregs

To investigate the possible relationship between CD25<sup>high</sup> and CD25<sup>low</sup> FOXP3<sup>+</sup>HELIOS<sup>+</sup> Tregs, we hypothesized that if CD25<sup>high</sup> FOXP3<sup>+</sup>HELIOS<sup>+</sup> Tregs are the precursors of the CD25<sup>low</sup> FOXP3<sup>+</sup>HELIOS<sup>+</sup> T cell subset, the numbers of CD25<sup>high</sup> Tregs in cycle (Ki-67<sup>+</sup>) and CD25<sup>low</sup> FOXP3<sup>+</sup>HELIOS<sup>+</sup> T cells should be



**Fig. 7. Proliferating Ki-67<sup>+</sup> CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> Tregs correlate with the frequencies of the CD25<sup>low</sup> and CD25<sup>high</sup> CD127<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> subsets.** (A, B) Data shown depict the correlation between the frequency within CD45RA<sup>-</sup> CD4<sup>+</sup> T cells of in-cycle (Ki-67<sup>+</sup>) CD4<sup>+</sup> CD45RA<sup>-</sup> CD127<sup>low</sup> CD25<sup>high</sup> Tregs (FOXP3<sup>+</sup> HELIOS<sup>+</sup>) and the frequency of either CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells (A) or conventional CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> Tregs (B). (C) Data shown depict the correlation between the frequencies of circulating CD4<sup>+</sup> CD45RA<sup>-</sup> CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> and CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells. Frequencies of the assessed immune subsets were measured in PBMCs from healthy volunteers from two independent cohorts: cohort 1 containing 24 donors (depicted in red) and cohort 2 containing 112 donors (depicted in black). The  $r^2$  values represent the coefficient of determination of the linear regression in the combined cohorts, and the  $P$  values correspond to the  $F$  statistic testing the null hypothesis that the slope of the linear regression analysis is equal to 0. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

correlated. This correlation would be required to maintain homeostasis of Treg numbers such that as memory CD25<sup>high</sup> Tregs are required to increase in peripheral compartments to respond to inflammatory conditions, a higher Treg turnover would lead to more CD25<sup>high</sup> Tregs moving into the CD25<sup>low</sup> compartment and ultimately to cell death. We assessed the total numbers of CD45RA<sup>-</sup> Ki-67<sup>+</sup> Tregs both in the cohort of 24 healthy volunteers (cohort 1) and in an independent replication cohort (cohort 2) of 112 healthy volunteers. We found that the frequency of CD45RA<sup>-</sup> CD4<sup>+</sup> Ki-67<sup>+</sup> CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> Tregs was significantly correlated with the frequency of CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells within total memory CD4<sup>+</sup> T cells ( $r^2 = 0.18$ ,  $P = 3.1 \times 10^{-7}$ ; Fig. 7A). Similarly, we observed a strong correlation between the numbers of in-cycle Ki-67<sup>+</sup> Tregs and the CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> Treg compartment ( $r^2 = 0.46$ ,  $P = 1.2 \times 10^{-19}$ ; Fig. 7B), as well as a significant correlation between both the total CD25<sup>low</sup> and CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cell compartments ( $r^2 = 0.15$ ,  $P = 3.9 \times 10^{-6}$ ; Fig. 7C). These observed correlations were very consistent within both cohorts of healthy volunteers, and suggest that proliferation of conventional CD25<sup>high</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells is critical to promote the homeostatic repopulation of the CD25<sup>high</sup> Treg subset, which is maintained at a steady state frequency through the progression of a proportion of CD25<sup>high</sup> Tregs to the CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> compartment.

#### 4. Discussion

The identification of reliable biomarkers of disease activity has been a major challenge of autoimmune diseases, particularly in organ-specific diseases, such as T1D, where there is limited access to the inflamed target tissues. In this study we characterised a subset of FOXP3<sup>+</sup> CD127<sup>low</sup> CD25<sup>low</sup> CD4<sup>+</sup> T cells, and show that it could be a peripheral biomarker of a recent or chronic autoimmune or cytokine-driven inflammatory reaction in the tissues. We showed that in addition to SLE, where the increase of FOXP3<sup>+</sup> CD25<sup>low</sup> T cells has been observed in multiple studies [5–9], the proportion of FOXP3<sup>+</sup> cells in the CD127<sup>low</sup> CD25<sup>low</sup> subset is increased in CID and T1D patients. Although the frequency of FOXP3<sup>+</sup> cells in the CD127<sup>low</sup> CD25<sup>low</sup> subset was compared in T1D patients versus controls in one previous study with no difference observed [13], we note that the number of participants was small: 10 healthy control individuals and 16 patients. In contrast, Zoka

et al. [18] observed that the proportion of CD25<sup>low</sup> cells among FOXP3<sup>+</sup> CD4<sup>+</sup> T cells is higher in T1D patients than in controls, a phenotype consistent with our observations.

A major strength of this study is that we were able to use a recently developed assay [16] to precisely assess the methylation status of the FOXP3 TSDR of CD25<sup>low</sup> FOXP3<sup>+</sup> cells, a feature that was lacking in the previous SLE studies [7,8] or studies of this subset from healthy individuals [13]. This method provides a more quantitative assessment of the methylation pattern of the FOXP3 locus [16] in the different immune subsets, which allowed us to demonstrate that the epigenetic profile of CD25<sup>low</sup> FOXP3<sup>+</sup> cells was remarkably similar to conventional CD25<sup>high</sup> FOXP3<sup>+</sup> Tregs (57.1% and 80.5% demethylated at the TSDR, respectively). We went on to define that this epigenetic similarity was caused primarily by the TSDR methylation status of HELIOS<sup>+</sup> cells: virtually all HELIOS<sup>+</sup> cells were found to be demethylated in both the CD25<sup>high</sup> and CD25<sup>low</sup> FOXP3<sup>+</sup> subsets. This finding is consistent with a previous study assessing the FOXP3 TSDR methylation profile in different CD4<sup>+</sup> CD127<sup>low</sup> T-cell subsets discriminated by their expression of FOXP3 and CD25 [19]. The majority of CD25<sup>low</sup> FOXP3<sup>+</sup> cells sorted from synovial fluid mononuclear cells of juvenile idiopathic arthritis patients were shown to have a demethylated FOXP3 TSDR, suggesting that this subset may be enriched at inflammatory sites [19]. In the current study we also found that the proportion of cells expressing TIGIT was elevated over 2-fold in both FOXP3<sup>+</sup> HELIOS<sup>+</sup> subsets as compared to their FOXP3<sup>+</sup> HELIOS<sup>-</sup> counterparts. Stable demethylation of the FOXP3 TSDR occurs in the thymus upon strong T-cell receptor stimulation [1], therefore suggesting that CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> cells are *bona-fide* thymically-derived Tregs that have lost the expression of CD25.

In further support of the hypothesis that CD25<sup>low</sup> FOXP3<sup>+</sup> HELIOS<sup>+</sup> T cells could be a subset of the classical FOXP3<sup>+</sup> Treg subset, these cells were unable to produce IL-2 following *in vitro* activation. This finding was in contrast with the report by Yang *et al* [8] that CD25<sup>low</sup> FOXP3<sup>+</sup> T cells from new-onset SLE patients were able to secrete IL-2. However, we note that the IL-2 production reported in Yang *et al* was much lower compared to CD25<sup>high</sup> FOXP3<sup>+</sup> T cells, and immune subsets were not stratified based on the expression of CD127, CD45RA and HELIOS. It is therefore likely that the residual production of IL-2 observed by Yang *et al* in CD25<sup>low</sup> FOXP3<sup>+</sup> T cells was due primarily to HELIOS<sup>-</sup> T cells. In contrast, in our study we demonstrate that CD45RA<sup>-</sup>

CD25<sup>low</sup>CD127<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> cells have a profound inability to produce IL-2 as compared to CD127<sup>+</sup>CD25<sup>high</sup> CD45RA<sup>-</sup> HELIOS<sup>-</sup>FOXP3<sup>-</sup> Tregs. We also noted the overall heterogeneity in the CD127<sup>low</sup> subset in regard to IL-2 and IFN- $\gamma$  secretion (Fig. 6). A similar proportion of CD127<sup>low</sup> cells lacking both FOXP3 and HELIOS expression secrete IL-2 and IFN- $\gamma$  as compared to their CD127<sup>+</sup> counterparts and are likely effector T cells. In healthy individuals we observed that these putative effector cells are the largest portion of the CD45RA<sup>-</sup> CD25<sup>low</sup>CD127<sup>low</sup> gate (Fig. 1B), consistent with previous observations [13].

In addition to reduced levels of CD25, CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> Tregs had lower expression of CTLA-4, CD15s and FOXP3 as compared to CD25<sup>high</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> Tregs, suggesting that CD25<sup>low</sup> Tregs could have decreased suppressive function. One limitation of our study is that we are not able to directly assess the suppressive capacity of CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> cells, as sorting on the intracellular transcription factors precludes the use of these cells for functional assays and surrogate surface markers are not yet defined. Also, as described above, the CD45RA<sup>-</sup> CD25<sup>low</sup>CD127<sup>low</sup> gate has a high proportion of effector cells present, making the results of suppression experiments using populations of cells gated as CD25<sup>low</sup>CD127<sup>low</sup> difficult to interpret. Notably, despite the cellular heterogeneity inherent in the CD25<sup>low</sup>CD127<sup>low</sup> subset, two studies did test the suppressive capacity of sorted CD25<sup>low</sup>CD127<sup>low</sup> CD4<sup>+</sup> T cells [7,13]. Suppression of proliferation by Tregs was mediated by CD25<sup>low</sup>CD127<sup>low</sup> CD4<sup>+</sup> T cells in both studies; however IFN- $\gamma$  secretion by Tregs was not suppressed in the one study that examined this parameter [7]. The reduced suppression mediated by CD25<sup>low</sup>CD127<sup>low</sup> CD4<sup>+</sup> T cells could be due to the fact that a larger proportion of effector cells are present in this subset as compared with their CD25<sup>+</sup> counterparts. Overall the observation of suppression by CD25<sup>low</sup>CD127<sup>low</sup> CD4<sup>+</sup> T cells supports the conclusion that the CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> Tregs present in the heterogeneous CD25<sup>low</sup>CD127<sup>low</sup> CD4<sup>+</sup> T cell population are functionally suppressive. Future studies are needed to unravel the heterogeneity present in both the CD25<sup>low</sup> and CD25<sup>high</sup> CD127<sup>low</sup>CD4<sup>+</sup> T cell subsets.

An increased frequency of CD25<sup>low</sup> FOXP3<sup>+</sup> Tregs has now been reported in a growing number of autoimmune diseases, including SLE, rheumatoid arthritis and multiple sclerosis [5–11]. In this study we expanded this observation to patients with CID and T1D, suggesting a common mechanism of CD25<sup>low</sup> FOXP3<sup>+</sup> Tregs in countering effector T cells as well as other cells promoting inflammation. Further characterisation of CD25<sup>low</sup> FOXP3<sup>+</sup> Tregs in longitudinal studies correlating their frequencies with disease status and in response to therapeutic interventions would help determine their value as biomarkers. One study has shown in a small group of patients that treatment with glucocorticoids and cyclophosphamide decreased the frequency of CD25<sup>low</sup> FOXP3<sup>+</sup> Tregs in SLE patients [5].

In our study we have provided a detailed phenotypic characterisation of CD25<sup>low</sup> as compared to conventional CD25<sup>high</sup> FOXP3<sup>+</sup> Tregs. In contrast to the reduced expression of several molecules that are abundant in CD25<sup>high</sup> FOXP3<sup>+</sup> Tregs such as CTLA-4, CD15s and FOXP3 itself, the frequency of cells expressing PD-1 and Ki-67 in CD25<sup>low</sup> Tregs was higher than in conventional CD25<sup>high</sup> Tregs, suggesting that the CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> population may represent the consequences of CD25<sup>high</sup> Tregs attempting to suppress ongoing inflammatory responses in tissues. The progression of CD25<sup>high</sup> Tregs to the CD25<sup>low</sup> Treg subset is supported by our observation of the strong correlation between the frequency of CD25<sup>high</sup> Tregs in cell cycle (Ki-67<sup>+</sup>) with the number of CD25<sup>low</sup> Tregs. The high proportion (15–40%) of memory FOXP3<sup>+</sup> Tregs in cycle is consistent with their shorter half-lives as compared to other T cell subsets [20,21]. Thus, given the fact that

Treg percentages normally remain constant in an individual through time [21], and a high proportion of the cells are replicating, Treg cell death must be a common outcome following cell division. We propose that the decreased expression of CD25 on Tregs, most likely caused by exposure to inflammatory conditions, causes less responsiveness to IL-2, reduced expression of FOXP3 and other Treg-associated molecules, and an increased probability of cell death. Despite the reduced IL-2 responsiveness in CD25<sup>low</sup> Tregs, it is possible that the Tregs remain functional and that the upregulation of PD-1 could compensate for reductions in FOXP3 and CTLA-4 levels [22]. Consistent with this hypothesis, previous studies have reported that PD-1 is a critical inhibitory molecule that is upregulated on T cells after activation [23–25]. In contrast, chronic PD-1 signaling within peripheral compartments has been reported to lead to reduced STAT5 phosphorylation, decreased expression of CD25, FOXP3 and CTLA-4, and decreased Treg suppressive function [26–28]. Additional functional studies are required to resolve these apparently contradictory mechanisms.

## 5. Conclusions

We hypothesize that the presence of a low frequency of CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> cells in peripheral blood from healthy individuals reflects a normal physiological mechanism to maintain, genetically-regulated, Treg levels. Their increased frequency in peripheral blood from autoimmune patients, which is particularly noteworthy in patients with chronic systemic inflammation, is indicative of an inflammatory insult that drives the expansion of the Treg population, which can be transient or chronic, in an attempt to regulate an overt autoimmune Treg response. Given the paucity of reliable peripheral biomarkers of disease activity, our findings suggest that the frequency of CD25<sup>low</sup> HELIOS<sup>+</sup>FOXP3<sup>+</sup> Tregs could provide valuable information about recent or ongoing tissue inflammation and could have a clinical application for the stratification of patients with autoimmunity.

## Author contributions

R.C.F., J.A.T., L.S.W. and M.L.P. designed experiments and interpreted data. R.C.F., H.Z.S., W.S.T., D.B.R., A.J.C., J.O., X.C.D., D.J.S., N.S., M.M. and M.L.P. performed experiments. X.Y. analysed the data. C.W. supervised the statistical analysis of the data. T.J.V., D.B.D., H.B. and A.C. provided samples and clinical outcome data. R.C.F., J.A.T., L.S.W. and M.L.P. conceived the study and wrote the paper.

## Acknowledgements

This work was supported by the JDRF UK Centre for Diabetes - Genes, Autoimmunity and Prevention (D-GAP; 4-2007-1003) in collaboration with M. Peakman and T. Tree at Kings College London, a strategic award to the Diabetes and Inflammation Laboratory from the JDRF (9-2011-253) and the Wellcome Trust (WT; WT061858/091157), and the National Institute for Health Research Cambridge Biomedical Research Centre. RCF is funded by an advanced JDRF post-doctoral fellowship (2-APF-2017-420-A-N). CW is funded by the Wellcome Trust (088998).

We thank staff of the National Institute for Health Research (NIHR) Cambridge BioResource recruitment team for assistance with volunteer recruitment and K. Beer, T. Cook, S. Hall and J. Rice of the Cambridge BioResource for blood sample collection. We thank C. Guy from the Department of Paediatrics, University of Cambridge for D-GAP sample recruitment. We thank M. Woodburn and T. Attwood from the Diabetes and Inflammation Laboratory, University of Cambridge for their contribution to sample management and N. Walker and H. Schuilenburg from the Diabetes and Inflammation



Laboratory, University of Cambridge for data management. This research was supported by the Cambridge NIHR BRC Cell Phenotyping Hub. In particular, we wish to thank Anna Petrunikina Harrison, Simon McCullum, Christopher Bowman and Esther Perez from the Cambridge NIHR BRC Cell Phenotyping Hub for their advice and support in cell sorting. We thank Howard Martin, Fay Rodger and Ruth Littleboy for running the Illumina MiSeq in the Molecular Genetics Laboratories, Addenbrooke's Hospital, Cambridge. We thank members of the NIHR Cambridge BioResource SAB and management committee for their support and the NIHR Cambridge Biomedical Research Centre for funding. Access to NIHR Cambridge BioResource volunteers and their data and samples is governed by the NIHR Cambridge BioResource SAB. Documents describing access arrangements and contact details are available at <http://www.cambridgebioresource.org.uk/>. We also thank H. Stevens, P. Clarke, G. Coleman, S. Dawson, S. Duley, M. Maisuria-Armer and T. Mistry from the Diabetes and Inflammation Laboratory, University of Cambridge for preparation of PBMC samples.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.jaut.2017.07.009>.

#### References

- [1] N. Ohkura, M. Hamaguchi, H. Morikawa, K. Sugimura, A. Tanaka, Y. Ito, M. Osaki, Y. Tanaka, R. Yamashita, N. Nakano, J. Huehn, H.J. Fehling, T. Sparwasser, K. Nakai, S. Sakaguchi, T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development, *Immunity* 37 (2012) 785–799.
- [2] M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taffin, T. Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura, G. Gorochov, S. Sakaguchi, Functional delineation and differentiation dynamics of human CD4<sup>+</sup> T cells expressing the FoxP3 transcription factor, *Immunity* 30 (2009) 899–911.
- [3] K. Bin Dhuban, E. D'Hennezel, E. Nashi, A. Bar-Or, S. Rieder, E.M. Shevach, S. Nagata, C.A. Piccirillo, Coexpression of TIGIT and FCRL3 identifies Helios<sup>+</sup> human memory regulatory T cells, *J. Immunol.* 194 (2015) 3687–3696.
- [4] C.A. Fuhrman, W.-I. Yeh, H.R. Seay, P. Saikumar Lakshmi, G. Chopra, L. Zhang, D.J. Perry, S.A. McClymont, M. Yadav, M.-C. Lopez, H. V Baker, Y. Zhang, Y. Li, M. Whitley, D. von Schack, M.A. Atkinson, J.A. Bluestone, T.M. Brusko, Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226, *J. Immunol.* 195 (2015) 145–155.
- [5] B. Zhang, X. Zhang, F.L. Tang, L.P. Zhu, Y. Liu, P.E. Lipsky, Clinical significance of increased CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells in patients with new-onset systemic lupus erythematosus, *Ann. Rheum. Dis.* 67 (2008) 1037–1040.
- [6] R.K. Chowdhary Venigalla, T. Tretter, S. Krienke, R. Max, V. Eckstein, N. Blank, C. Fiehn, A. Dick Ho, H.-M. Lorenz, Reduced CD4<sup>+</sup>CD25<sup>+</sup> T cell sensitivity to the suppressive function of CD4<sup>+</sup>CD25<sup>high</sup>CD127<sup>+</sup>/low regulatory T cells in patients with active systemic lupus erythematosus, *Arthritis Rheum.* 58 (2008) 2120–2130.
- [7] M. Bonelli, A. Savitskaya, C.-W. Steiner, E. Rath, J.S. Smolen, C. Scheinecker, Phenotypic and functional analysis of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells in patients with systemic lupus erythematosus, *J. Immunol.* 182 (2009) 1689–1695.
- [8] H. Yang, W. Zhang, L. Zhao, Y. Li, F. Zhang, F. Tang, W. He, X. Zhang, Are CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cells in untreated new-onset lupus patients regulatory T cells? *Arthritis Res. Ther.* 11 (2009) 1–9.
- [9] J.-L. Suen, H.-T. Li, Y.-J. Jong, B.-L. Chiang, J.-H. Yen, Altered homeostasis of CD4<sup>+</sup> FoxP3<sup>+</sup> regulatory T-cell subpopulations in systemic lupus erythematosus, *Immunology* 127 (2009) 196–205.
- [10] M. Fransson, J. Burman, C. Lindqvist, C. Atterby, J. Fagius, A. Loskog, T regulatory cells lacking CD25 are increased in MS during relapse, *Autoimmunity* 43 (2010) 590–597.
- [11] B. de Paz, C. Prado, M. Alperi-López, F.J. Ballina-García, J. Rodríguez-Carrio, P. López, A. Suárez, Effects of glucocorticoid treatment on CD25<sup>+</sup>FoxP3<sup>+</sup> population and cytokine-producing cells in rheumatoid arthritis, *Rheumatology* 51 (2012) 1198–1207.
- [12] D.A. Horwitz, Identity of mysterious CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cells in SLE, *Arthritis Res. Ther.* 12 (2010) 101.
- [13] W. Liu, A.L. Putnam, Z. Xu-yu, G.L. Szot, M.R. Lee, S. Zhu, P.A. Gottlieb, P. Kapranov, T.R. Gingeras, B.F. de St. Groth, C. Clayberger, D.M. Soper, S.F. Ziegler, J.A. Bluestone, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4<sup>+</sup> T reg cells, *J. Exp. Med.* 203 (2006) 1701–1711.
- [14] H.S. Kuehn, W. Ouyang, B. Lo, E.K. Deenick, J.E. Niemela, D.T. Avery, J.-N. Schickel, D.Q. Tran, J. Stoddard, Y. Zhang, D.M. Frucht, B. Dumitriu, P. Scheinberg, L.R. Folio, C.A. Frein, S. Price, C. Koh, T. Heller, C.M. Seroogy, A. Huttenlocher, V.K. Rao, H.C. Su, D. Kleiner, L.D. Notarangelo, Y. Rampertaap, K.N. Olivier, J. McElwee, J. Hughes, S. Pittaluga, J.B. Oliveira, E. Meffre, T.A. Fleisher, S.M. Holland, M.J. Lenardo, S.G. Tangye, G. Uzel, Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4, *Science* 345 (2014) 1623–1627.
- [15] W.S. Thompson, M.L. Pekalski, H.Z. Simons, D.J. Smyth, X. Castro-Dopico, H. Guo, C. Guy, D.B. Dunger, S. Arif, M. Peakman, C. Wallace, L.S. Wicker, J.A. Todd, R.C. Ferreira, Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes, *Clin. Exp. Immunol.* 177 (2014) 571–585.
- [16] D.B. Rainbow, X. Yang, O. Burren, M.L. Pekalski, D.J. Smyth, M.D.R. Klarqvist, C.J. Penkett, K. Brugger, H. Martin, J.A. Todd, C. Wallace, L.S. Wicker, Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing, *Eur. J. Immunol.* 45 (2015) 3200–3203.
- [17] S.A. McClymont, A.L. Putnam, M.R. Lee, J.H. Esensten, W. Liu, M.A. Hulme, U. Hoffmüller, U. Baron, S. Olek, J.A. Bluestone, T.M. Brusko, Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes, *J. Immunol.* 186 (2011) 3918–3926.
- [18] A. Zóka, G. Barna, A. Somogyi, G. Múzes, Á. Oláh, Z. Al-Aissa, O. Hadarits, K. Kiss, G. Firneisz, Extension of the CD4<sup>+</sup>Foxp3<sup>+</sup>CD25<sup>+</sup>/low regulatory T-cell subpopulation in type 1 diabetes mellitus, *Autoimmunity* 48 (2015) 289–297.
- [19] D. Bending, A.M. Pesenacker, S. Ursu, Q. Wu, H. Lom, B. Thirugnanabalan, L.R. Wedderburn, Hypomethylation at the regulatory T cell-specific demethylated region in CD25<sup>hi</sup> T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis, *J. Immunol.* 193 (2014) 2699–2708.
- [20] M. Vukmanovic-Stejić, Y. Zhang, J.E. Cook, J.M. Fletcher, A. McQuaid, J.E. Masters, M.H.A. Rustin, L.S. Taams, P.C.L. Beverley, D.C. Macallan, A.N. Akbar, Human CD4<sup>+</sup> CD25<sup>hi</sup> Foxp3<sup>+</sup> regulatory T cells are derived by rapid turnover of memory populations in vivo, *J. Clin. Investig.* 116 (2006) 2423–2433.
- [21] J.B. Bollyky, S.A. Long, M. Fitch, P.L. Bollyky, M. Rieck, R. Rogers, P.L. Samuels, S. Sanda, J.H. Buckner, M.K. Hellerstein, C.J. Greenbaum, Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes, *Clin. Exp. Immunol.* 172 (2013) 363–374.
- [22] T. Asano, Y. Meguri, T. Yoshioka, Y. Kishi, M. Iwamoto, M. Nakamura, Y. Sando, H. Yagita, J. Koreth, H.T. Kim, E.P. Alyea, P. Armand, C.S. Cutler, V.T. Ho, J.H. Antin, R.J. Soiffer, Y. Maeda, M. Tanimoto, J. Ritz, K. Matsuoka, PD-1 modulates regulatory T cell homeostasis during low-dose IL-2 therapy, *Blood* 129 (2017) 2186–2197.
- [23] A.H. Sharpe, E.J. Wherry, R. Ahmed, G.J. Freeman, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, *Nat. Immunol.* 8 (2007) 239–245.
- [24] B.T. Fife, J.A. Bluestone, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, *Immunol. Rev.* 224 (2008) 166–182.
- [25] L.M. Francisco, P.T. Sage, A.H. Sharpe, The PD-1 pathway in tolerance and autoimmunity, *Immunol. Rev.* 236 (2010) 219–242.
- [26] D. Franceschini, M. Paroli, V. Francavilla, M. Videtta, S. Morrone, G. Labbadia, A. Cerino, M.U. Mondelli, V. Barnaba, PD-L1 negatively regulates CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV, *J. Clin. Investig.* 119 (2009) 551–564.
- [27] P.T. Sage, L.M. Francisco, C. V Carman, A.H. Sharpe, The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood, *Nat. Immunol.* 14 (2013) 152–161.
- [28] M. Wong, A. La Cava, B.H. Hahn, Blockade of programmed Death-1 in young (New Zealand black × New Zealand White)F1 mice promotes the suppressive capacity of CD4<sup>+</sup> regulatory T cells protecting from lupus-like disease, *J. Immunol.* 190 (2013) 5402–5410.